Raymond James Lowers Danaher (NYSE:DHR) Price Target to $275.00

Danaher (NYSE:DHR) had its price target reduced by analysts at Raymond James from $300.00 to $275.00 in a note issued to investors on Tuesday,Benzinga reports. The firm currently has an “outperform” rating on the conglomerate’s stock. Raymond James’ target price suggests a potential upside of 12.58% from the stock’s previous close.

Other analysts have also recently issued reports about the company. Barclays lowered their target price on Danaher from $285.00 to $275.00 and set an “equal weight” rating on the stock in a research report on Wednesday, October 23rd. Bank of America raised shares of Danaher from a “neutral” rating to a “buy” rating and set a $290.00 price objective for the company in a report on Friday, December 13th. Scotiabank initiated coverage on shares of Danaher in a report on Monday, December 23rd. They issued a “sector perform” rating and a $265.00 price objective for the company. Evercore ISI lifted their target price on Danaher from $275.00 to $278.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. Finally, Citigroup reduced their price objective on Danaher from $305.00 to $285.00 and set a “buy” rating for the company in a research note on Monday, January 6th. Six research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. According to MarketBeat.com, Danaher presently has an average rating of “Moderate Buy” and an average target price of $285.55.

Danaher Stock Performance

Shares of DHR traded up $5.91 during mid-day trading on Tuesday, hitting $244.27. The stock had a trading volume of 837,604 shares, compared to its average volume of 2,983,475. The company has a quick ratio of 1.01, a current ratio of 1.37 and a debt-to-equity ratio of 0.32. The company has a market cap of $176.43 billion, a PE ratio of 46.64, a PEG ratio of 4.30 and a beta of 0.83. Danaher has a fifty-two week low of $225.42 and a fifty-two week high of $281.70. The company’s fifty day simple moving average is $234.75 and its two-hundred day simple moving average is $253.50.

Danaher (NYSE:DHR) last released its quarterly earnings data on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.57 by $0.14. The business had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.59 billion. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The business’s revenue for the quarter was up 3.1% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.02 EPS. On average, equities analysts expect that Danaher will post 7.49 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Coronation Fund Managers Ltd. boosted its position in Danaher by 29.9% during the second quarter. Coronation Fund Managers Ltd. now owns 6,389 shares of the conglomerate’s stock worth $1,596,000 after purchasing an additional 1,470 shares during the period. ProShare Advisors LLC boosted its holdings in shares of Danaher by 7.9% during the 2nd quarter. ProShare Advisors LLC now owns 96,531 shares of the conglomerate’s stock worth $24,118,000 after buying an additional 7,091 shares during the period. Mount Yale Investment Advisors LLC grew its stake in Danaher by 43.8% in the 2nd quarter. Mount Yale Investment Advisors LLC now owns 2,641 shares of the conglomerate’s stock valued at $660,000 after buying an additional 805 shares during the last quarter. EverSource Wealth Advisors LLC raised its holdings in Danaher by 12.1% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,531 shares of the conglomerate’s stock worth $424,000 after acquiring an additional 165 shares during the period. Finally, DRW Securities LLC acquired a new position in Danaher during the 2nd quarter worth $385,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.